key: cord-0848466-3xr0566m
authors: Calvani, Riccardo; Picca, Anna; Landi, Francesco; Marzetti, Emanuele
title: Plasma therapies and parabiosis in the COVID-19 era
date: 2020-06-16
journal: J Am Med Dir Assoc
DOI: 10.1016/j.jamda.2020.05.066
sha: dddc228958da6ab3558ca01d680bddc4774c2e26
doc_id: 848466
cord_uid: 3xr0566m

nan

1 Plasma therapies and parabiosis in the COVID-19 era 1 2 To the Editor: 3 4 A novel coronavirus (SARS-CoV-2), likely spilled over from bats, is causing a nightmarish 5 global pandemic and has ignited a worldwide race for the discovery of effective therapies against 6 COVID-19. The disease severity and lethality are clearly higher in older adults, with notable sex-7 specific differences. The impact of age on COVID-19 outcomes is reflected by case fatality rates in 8 older patients being up to 100-fold higher than in infants. 1 At all ages, men are more severely 9 affected than women. 1 An ageism-guided reallocation of medical resources to prioritize assistance 10 of younger patients may contribute to the excess mortality in older citizens. 2 Yet, the combined 11 effect of age and gender on COVID-19-related morbidity and mortality mirrors what is commonly 12 encountered in aging research and in major chronic diseases. 13

According to the geroscience paradigm, some molecular pathways, collectively called 14 "hallmarks of aging", underpin age-related derangements in physiological systems and cellular 15 processes. 3 Noticeably, these pillars of aging are also involved in the pathogenesis of conditions 16 that increase COVID-19 severity and lethality (e.g., hypertension, cardiovascular disease, diabetes). 17

Geroprotective treatments targeting inner mechanisms of aging might therefore be exploited to But convalescent plasma is much more than an antibody "soup". Rather, it contains all the 41 "molecular tools" the recipient will harness to heal from COVID-19. The repertoire of plasma-42 based factors that are transfused alongside with neutralizing antibodies includes anti-inflammatory 43 cytokines, anticlotting factors, natural antibodies, specialized pro-resolving mediators (e.g., 44

resolvins, protectins, maresins), defensins, pentaxins, collectins, plus an undefined number of 45 unknown mediators. 5 This molecular arsenal enhances viral clearance, engages B and T 46 lymphocytes, limits the inflammatory cascade, prevents microembolism, and promotes tissue 47 repair. 5 Anti-SARS-CoV-2 non-neutralizing antibodies that bind to the virus without impeding its 48 replication may still promote recovery through recruitment of innate immune cells. 5 49

The foreseeable increasing use of convalescent plasma to treat COVID-19 may also allow 50 exploring an intriguing hypothesis in the geriatric field. In heterochronic parabiosis experiments, 51 multiple organs, including lungs, liver, heart, kidney and brain, can be "rejuvenated" in old mice by 52 3 synergistic actions of young blood constituents. 11 Indeed, the plasma proteome harbors key 53 regulators of aging. 12 Because of the plausible interaction of aging biology with SARS-CoV-2 54 infection, the geroprotective properties of plasma from young convalescent donors could mitigate 55 COVID-19 severity in older adults to a greater extent than one might expect from the sole antibody 56 titer. Whether older men experience additional benefits from receiving plasma from young women 57 is also worth being explored. In conclusion, the ongoing COVID-19 pandemic and the lack of 58 effective pharmacological therapies have set the stage for the unprecedented opportunity to test on a 59 large scale one of the tenets of contemporary geroscience. 

Estimates of the severity of coronavirus disease 2019: a 66 model-based analysis

COVID-19 in Italy: ageism and decision making in a pandemic

The hallmarks of aging

A geroscience perspective on COVID-19 mortality

Convalescent plasma in Covid-19: possible 74 mechanisms of action

Treatment of 5 critically ill patients with COVID-19 with 76 convalescent plasma

Effectiveness of convalescent plasma therapy in severe COVID-78 19 patients

Deployment of convalescent plasma for the 80 prevention and treatment of COVID-19

The race is on for antibodies that stop the new coronavirus

Viral-induced enhanced disease illness

Heterochronic parabiosis for the study of the effects of aging on 86 stem cells and their niches

Undulating changes in human plasma proteome 88 profiles across the lifespan